The Von Willebrand Disease in Pregnancy (VIP) Study website VIPStudy.com will be launched alongside an educational webinar on von Willebrand disease for healthcare providers.

SEATTLE, November 29, 2021 / PRNewswire / – Co-Principal Investigators Drs. Jill johnsen, Barbara konkle and Pierre Kouides are pleased to announce that the VIPStudy.com website will be officially launched during an educational webinar on December 10e, 2021 to 10-11 a.m. EST.

The website educates patients and healthcare professionals about Von von Willebrand disease Im P(VIP) and provides information on study design, patient eligibility and location of participating centers.

Women with von Willebrand disease are at an increased risk of excessive bleeding during and after childbirth, which can lead to severe anemia, require a transfusion, or even lead to life-threatening blood loss. Even with specific treatment for von Willebrand disease, women with von Willebrand disease have relatively high rates of postpartum hemorrhage. However, there is a lack of clinical data on the optimal management of bleeding during and after childbirth in women with von Willebrand disease, and current guidelines do not specify target levels of von Willebrand factor (VWF). or the duration of treatment.

The VIP study aims to increase our understanding of bleeding during childbirth and the postpartum period in women with von Willebrand disease (VWD). It will also assess the impact of maintaining VWF levels at a specific target level using VWF replacement therapy on bleeding rates during and after childbirth.

The VIPStudy.com website will be launched in a webinar hosted by Dr Johnsen on Friday December 10e To 10-11 a.m. EST, just before this year’s American Society of Hematology (ASH) annual meeting. VWD Experts Drs. Paula james and Veronica flood will join Dr. Johnsen to discuss the challenges of diagnosing von Willebrand disease, managing heavy menstrual bleeding in women with von Willebrand disease, and the changing needs of pregnant women with von Willebrand disease. Webinar attendees will have the opportunity to interact with the speakers in a live question-and-answer session. More information about the webinar, including how to register, is available at https://webinar.docintel.app/VIP-study/login.php?utmevent=von_willbrand

The webinar will also be available for on-demand viewing.

Dr Johnsen commented: “This webinar will draw attention to the challenges faced by patients with von Willebrand disease, especially those who are menstruating or becoming pregnant. The VIP study website provides information about the VIP study, patient eligibility, and the location of study sites.

The VIP study is currently recruiting pregnant women over the age of 18 with von Willebrand disease of all types in the United States.

About the VIP study

The VIP study is a prospective, multicenter cohort study initiated by a researcher in the United States (NCT04146376). The principal investigators are Drs. Jill johnsen (contact PI, Bloodworks and Washington University), Barbara konkle (Washington University), and Dr. Pierre Kouides (Mary M. Gooley Hemophilia Center and Rochester University). The study is sponsored by Bloodworks, with financial support from Bloodworks and Octapharma.

About Bloodworks

Bloodworks is an independent, non-profit organization that harnesses donor donations to provide a safe and vital blood supply to 95% of hospitals in the Pacific Northwest. Our doctors are specialists in transfusion medicine and provide care to patients with bleeding disorders and other conditions. Our laboratories offer a variety of testing services to support organ and tissue transplantation as well as patient care. Our research institute is making scientific breakthroughs to help people live longer and healthier lives, locally and around the world.

Our mission is to save lives through research, innovation, education and excellence in blood, medical and laboratory services in partnership with our community.

Contact:
Dr. Jill johnsen
E-mail: [email protected]

SOURCE The VIP study


Source link

Comments are closed.